Capri Holdings Ltd vs Immunovant Inc. Common Stock — how do they compare? Capri Holdings Ltd trades at $14.95 (market cap $1.67B), while Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is far larger — about 3.7× Capri Holdings Ltd's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Immunovant Inc. Common Stock for 1 Days on average.
| CPRI | IMVT | |
|---|---|---|
Market Cap | $1.67B | $6.25B |
Volume | 3,722,279 | 1,755,411 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $44.96 |
52-Week Low | $12.71 | $17.03 |
Typical Hold Time | 41 Days | 1 Days |
Enterprise Value | $2.95B | $5.35B |
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up 1.66% today, with a bullish technical signal from moving averages. The stock shows strong earnings beats recently but faces fundamental headwinds with a net loss of $1.18 billion in 2025 and declining revenue. Analyst consensus is a buy with a $20.57 price target, though sentiment is mixed due to Michael Kors brand challenges. Recent news highlights brand revitalization efforts and second-half growth expectations.
The outlook is cautiously optimistic given low valuation multiples and earnings beats, but significant risks include persistent revenue declines, high debt, and execution risks in the brand turnaround. The stock offers potential upside if operational improvements materialize, but investors must weigh turnaround progress against financial volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →